Summary: Venous thromboembolism (VTE) is a major cause of maternal morbidity during pregnancy and the postpartum period. However, because there is a lack of adequate study data, management strategies for pregnancy-associated VTE must be deduced from observational studies and extrapolated from recommendations for non-pregnant patients. In this review, the members of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH) have summarised the evidence that is currently available in the literature to provide a practical approach for treating pregnancy-associated VTE. Because heparins do not cross the placenta, weight-adjusted therapeutic-dose low molecular weight heparin (LMWH) is the anticoagulant treatment of choice in cases of acute VTE during pregnancy. No differences between once and twice daily LMWH dosing regimens have been reported, but twice daily dosing seems to be advisable, at least peripartally. It remains unclear whether determining dose adjustments according to factor Xa activities during pregnancy provides any benefi t. Management of delivery deserves attention and mainly depends on the time interval between the diagnosis of VTE and the expected delivery date. In particular, if VTE manifests at term, delivery should be attended by an experienced multidisciplinary team. In lactating women, an overlapping switch from LMWH to warfarin is possible. Anticoagulation should be continued for at least 6 weeks postpartum or for a minimum period of 3 months. Although recommendations are provided for the treatment of pregnancy-associated VTE, there is an urgent need for well-designed prospective studies that compare different management strategies and defi ne the optimal duration and intensity of anticoagulant treatment. 
Introduction
There is a paucity of studies addressing the diagnostic strategies and the risks and benefi ts of antithrombotic therapy during pregnancy. In a recently published article, we systematically reviewed the current evidence for the diagnostic management of deep vein thrombosis (DVT) and pulmonary embolism (PE) and provided a diagnostic algorithm for their diagnosis during pregnancy and the postpartum period. The present article is a state of the art review of treatment strategies for pregnancyassociated venous thromboembolism (VTE). It is clear that pregnant women have been excluded from all major phase III trials that have investigated the effi cacy and safety of diff erent anticoagulant regimens. Because of a lack of appropriate study data, treatment strategies are mainly extrapolated from studies of non-pregnant patients while considering the specifi c risks and benefi ts in both pregnant women and foetuses. Pregnant women who present with acute VTE, particularly in cases of proximal DVT or PE, should be hospitalised or followed closely when treated as outpatients. The risk of VTE recurrence is the highest within the fi rst 2 - 3 weeks after the initial diagnosis. , and Rupert Bauersachs 7, 8 nancy is limited [14 -16] . They should be considered second-line drugs in cases in which severe side eff ects result from LMWH or UFH (e.g., heparin-induced skin lesions, HIT). VKA, such as phenprocoumon or warfarin, cross the placenta and have the potential to cause both teratogenicity and foetal bleeding. Women with pregnancyassociated VTE should therefore not be treated with VKA. There have not been any human studies assessing the safety and effi cacy of novel oral anticoagulants (NOACs), such as the direct thrombin inhibitor dabigatran etexilate or the factor Xa inhibitors rivaroxaban, apixaban or edoxaban in pregnant or breast-feeding women, but these NOACs are thought to cross the placenta barrier, therefore leading to anticoagulation within the foetus, and can also be secreted into the breast milk. Animal studies of dabigatran and rivaroxaban revealed that they caused teratogenic eff ects, placental abnormalities, foetal haemorrhage and reduced foetal viability. Their use is therefore not recommended in pregnancy or during lactation [17 -20] .
Recommendation 1 -Heparins do not cross the placenta barrier. They are therefore the pharmacologic agents of choice for the treatment of VTE during pregnancy. In general, subcutaneously administered full-dose weight-adjusted LMWH is preferred over UFH. According to current evidence, there is no support for the routine use of VKA, NOACs, fondaparinux or danaparoid in uncomplicated pregnancy-associated VTE. However, fondaparinux and danaparoid are a therapeutic option if heparins are contraindicated due to adverse side effects.
LMWH -once or twice daily dosing
During the acute phase of DVT or PE, LMWH are usually administered in a full-dose, weight-adjusted, once-daily or twice-daily regimen. Table I describes the common dosing regimens used for the treatment of pregnancy-associated VTE. It has been suggested that a twice-daily regimen (e.g., dalteparin 100 IE/kg twice daily or enoxaparin 1 mg/kg twice daily) may be superior to once-daily dosing (e.g., tinzaparin 175 IE/kg once daily or dalteparin 200 IE/kg once daily) because of lower peak levels and the consequently lower bleeding risk [21, 22] . However, there are no clinical data to support this hypothesis. The glomerular fi ltration rate increases by approximately 50 % after the 15 th week of gestation, and as a consequence, LWMH clearance is also expected to increase. However, the data on this topic are confl icting [21, 23] . Two studies investigating the pharmacological profi le of enoxaparin in pregnancy revealed a decrease in peak aXa levels at 3 hours after subcutaneous injection and an increase in trough aXa activities, which the authors attributed to an increase in plasma volume and the apparent volume of distribution [24, 25] . The authors concluded that the consecutive prolongation of enoxaparin elimination half-life that was observed during the progress of pregnancy favoured a once-daily dose regimen in pregnant patients and that determining dose adjustments based on peak aXa levels may not be appropriate during pregnancy. No diff erence in clinical outcomes has been observed in small observational studies wherein women using oncedaily and twice-daily regimens throughout pregnancy were compared [26, 27] . The recently updated Royal College of Obstetricians & Gynaecologists guidelines state that there is insuffi cient evidence to recommend whether LMWH should be given once daily or in two divided doses [13] .
Recommendation 2 -Once or twice daily dosing regimens of fulldose weight-adjusted LMWH are acceptable for the treatment of acute VTE during pregnancy. On the basis of current evidence, once daily dosing seems to be suitable, and limits the number of injections. Although it is uncertain whether twice daily dosing is attended by a lower bleeding risk, the authors advocate switching to a twice daily dosing regimen perinatally because this may avoid high aXa levels at the time of delivery.
LMWH -maintenance therapy
Women with antenatal VTE are usually managed with LMWH for the remainder of pregnancy and during the postpartum period. There is no doubt regarding the use of a full-dose weight-adjusted LMWH regimen in the initial phase of VTE therapy. However, it remains unclear whether the initial therapeutic dose of LMWH can be reduced after several weeks to an intermediate dose [28] . A dose reduction to 50 -75 % of the initial dose has been successfully established in non-pregnant patients who were treated in the long-term with LMWH because there were contraindications to oral anticoagulants or because there were underlying malignancies [8, 29, 30] . Whether a comparable strategy is also safe in pregnant women is uncertain. Because the risk of VTE increases with the number of gestational weeks, and because higher LMWH doses may be required to maintain therapeutic aXa levels, a continued full-dose LMWH regimen may be reasonable unless maternal bleeding risk is substantially high. On the other hand, it can be argued that cancer patients are at a much higher risk of treatment failure than pregnant women, which strengthens the rationale for a dose reduction. Furthermore, reducing the intensity of anticoagulant therapy will very likely also reduce the risk of bleeding complications. The use of intermediate doses of LMWH may be an attractive alternative to the use of full-dose anticoagulants, particularly if limited venous thrombosis occurs during early pregnancy in association with transient risk-factors other than the pregnancy itself (e.g., distal DVT following immobilisation). No recurrent events were observed in a prospective study of 66 pregnant women suffering from acute VTE who were treated with 50 -75 % of the full therapeutic dose from the 3 rd week onwards [31] . In a systemic review, Gandara et al. summarised the evidence from 4 studies that included 152 women with pregnancy-associated VTE who were treated with an intermediate LMWH dose for the secondary prevention of VTE throughout pregnancy [32] . An intermediate dose was defi ned as any dose lower than 75 % of the full dose and higher than a prophylactic dose. When either LMWH or UFH were used during the acute full-dose treatment phase, no women experienced VTE recurrence. The authors identifi ed only one recurrent DVT during ongoing pregnancy, and it occurred when a 50 % dose reduction was performed within 7 days after the diagnosis of DVT. However, the studies included in this review were not intended to answer the question of optimal dosing of LMWH for the secondary prevention of VTE. Recently, the same authors published the results of an electronic survey that assessed current practices for the management of pregnancy-associated VTE in Canada [33] . Of the 69 physicians who completed the survey, more than 70 % of the respondents favoured a long-term treatment with full doses of LMWH during pregnancy.
Recommendation 3 -Because there are no studies comparing fulldose LMWH to modifi ed dose regimens in pregnant patients, it remains unclear whether the full therapeutic dose can be reduced to an intermediate dose regimen for the secondary prevention of VTE during ongoing pregnancy. In particular, a dose reduction should be considered during the course of pregnancy in women at high risk for bleeding complications or in whom the risk of VTE recurrence is supposed to be low.
Monitoring LMWH during pregnancy
It is still a matter of debate whether it is useful to use measurements of anti-factor-Xa (aXa) levels to determine consecutive dose adjustments in pregnant women receiving LMWH treatment. Inter-assay and inter-laboratory variability in aXa measurements have been described in nonpregnant and pregnant patients that were treated with therapeutic-doses of LMWH, and the validity of using peak aXa levels as a marker of antithrombotic activity has been questioned [23, 34 -36] . Moreover, several prospective observational studies have demonstrated that only a few pregnant patients required dose adjustments according to aXa levels when enoxaparin, dalteparin or tinzaparin were administered at therapeutic doses [37 -41] (Tab. II). In contrast, the results of other studies have indicated that higher LMWH doses are required to achieve therapeutic anti-Xa levels in progressing pregnancy. Jacobsen et al. treated 20 pregnant VTE patients with dalteparin (100 U/kg bid) and observed that a 10 -20 % higher dose of dalteparin was required to obtain therapeutic aXa levels than in non-pregnant women [42] . Barbour et al. measured peak and trough aXa levels in 13 pregnant women who received therapeutic doses of dalteparin (100 U/kg bid) and found that dose adjustment based on weight alone was inadequate to maintain aXa levels between 0.5 and 1.0 U/ml [43] . In their study, approximately 85 % of pregnant patients required a dose increase to achieve peak aXa activity in the therapeutic range, whereas the majority of trough levels were subtherapeutic (i.e., < 0.5 U/ml). In the above-mentioned studies, a total of 141 pregnant women treated with diff erent LMWHs were investigated. In these studies, there was no agreement regarding the optimal time interval that should be used between heparin injection and blood withdrawal to measure peak aXa levels. Some studies measured only peak aXa levels, whereas others also measured trough levels. Currently, no clinical endpoint studies have demonstrated an increase in effi cacy and safety outcomes, such as VTE recurrence or bleeding risk, when aXa monitoring and consecutive dose adjustment are performed. Moreover, the existing data are insuffi cient to answer the question of how to monitor and adjust LMWH dosing to optimise anticoagulant treatment during pregnancy.
Thus, current guidelines do not generally recommend routine aXa monitoring during pregnancy [8, 11, 13] . The 2015 version of the Royal College of Obstetricians and Gynaecologists (RCOG) guidelines states that measuring aXa peak levels may be considered in women at the extremes of body weight (i.e., < 50 or > 100 kg) or in women with other complicating factors, such as renal impairment, severe thrombophilia, and recurrent VTE despite anticoagulant therapy [13] . Because heparins exert their activity by binding to antithrombin, their anticoagulant eff ect may be attenuated in antithrombin-defi cient women. Generally, therapeutic aXa levels can be achieved by increasing heparin doses, which may require supra-therapeutic doses or the co-administration of antithrombin [44] .
However, a recent survey assessed current practices used to manage pregnancy-associated VTE, and revealed that 55/69 physicians performed aXa-monitoring in patients being treated with LMWH during pregnancy [33] . When LMWH monitoring and dose-adjustment are considered, measurements of aXa peak levels every 4-6 weeks should be taken using blood sampling within 2-4 hours after subcutaneous LMWH injection. No data have indicated a different aXa target range for pregnant women compared to non-pregnant patients. Therefore, dose adjustment may be performed to maintain a therapeutic aXa level (e.g., 0.6 -1.0 U/mL when a twice daily regimen is used and 0.8 -1.3 U/mL when LMWH is administered once daily) [45] . In clinical practice, women are advised to inject themselves in the morning to allow for blood sampling within 2 -4 hours after subcutaneous LMWH injection. Recommendation 4 -According to current evidence, using routine aXa measurement to monitor LMWH therapy during pregnancy cannot be recommended. Clinical endpoint studies assessing the risks of VTE recurrence and bleeding complications are strongly needed to clarify whether pregnant women will actually benefi t from monitoring and dose adjustment strategies. However, the measurement of aXa levels may be helpful when the risk of recurrent VTE is thought to be high, in cases of treatment failure (i.e., VTE recurrence despite adequate dosing), or when bleeding complications occur. In women at the extremes of body weight (i.e., < 50 or > 100 kg) and in those with renal insuffi ciency, aXa measurement may also be considered. We recommend the use of aXa monitoring and dose-adjustment to achieve therapeutic aXa levels in antithrombin-defi cient women with pregnancy-associated VTE.
Anticoagulant therapy with UFH
Unfractionated heparin may be considered as an alternative when LMWH cannot be used or when UFH is thought to be advantageous over LMWH, for example, in women with acute VTE after the 36 th week of gestation, in women suspected of having massive PE, in women at high risk of developing bleeding complications or in women with severe renal impairment. When UFH is given at therapeutic doses, the administration of a loading dose (e.g., 80 U/kg) is recommended and is usually followed by a continuous intravenous infusion (e.g., 18 U/kg/h) to achieve a 1.5-to 2.5-fold prolongation of the aPTT. Treatment with UFH at therapeutic doses requires monitoring of aPTT to achieve a therapeutic 1.5-to 2.5-fold prolongation of the aPTT and an aPTT level that corresponds to an aXa level of 0.3 -0.7 U/mL [8, 11, 45] . In cases of intravenous administration, the aPTT must be determined 4-6 hours after the loading dose and subsequently after every change in infusion rate (Tab. III). When aPTT levels are within the therapeutic range, at least once daily testing must be performed.
UFH can also be administered subcutaneously through twice daily injections. In cases of subcutaneous administration, aPTT tests should be performed 5 - 6 h after injection to assure a therapeutic prolongation [45] . It is important to note that the aPTT response to UFH during pregnancy is often attenuated. This is probably because the levels of heparin-binding proteins, such as factor VIII and fi brinogen, increase during pregnancy. Consequently, higher heparin doses may be required to obtain aPTT values in the therapeutic range in pregnant women compared to those used in non-pregnant patients [13, 46, 47] .
Platelet count monitoring
The risk of HIT during pregnancy is thought to be low (approximately 1 in 4000 pregnancies) [48] . Therefore, current guidelines do not advocate routine platelet count monitoring [13, 48, 49] . However, performing platelet count monitoring every 2 -3 days between days 4 and 14 is recommended in pregnant women who are postoperative, who receive UFH for longer than 5 days [13, 49] .
Anticoagulant therapy during delivery
The management of anticoagulated women who are at term is challenging, and in these cases, close collaboration between the obstetrician, the anaesthesiologist, the neonatologist and the haemostaseologist is required. In highrisk pregnancies, delivery should take place in a tertiary care centre with specialist multidisciplinary team care. Several delivery options are possible, including spontaneous labour and delivery, the induction of labour, and elective caesarean section. Because caesarean section is associated with higher blood loss, an increased risk of wound complications in anticoagulated women and a higher risk of VTE, it should be reserved mainly for patients with obstetric indications [21, 50 -52] . Thus, vaginal delivery remains the preferred mode of delivery in women who are anticoagulated due to pregnancy-associated VTE.
Current guidelines recommend discontinuing LMWH at least 24 hours before caesarean section or the elective induction of labour [8, 13, 53] . However, many obstetricians do not consider the induction of labour to be necessary. As labour can begin at an unplanned time, it is important to advise anticoagulated women early that they must stop LMWH as soon as labour starts, which is indicated by either contractions or the rupture of membranes. A twicedaily administration of LWMH is recommended perinatally (e.g., 37 th week of gestation) to avoid high peak levels and to lower the risk of postpartum bleeding complications. If labour is prolonged and the risk of VTE recurrence is thought to be high, the administration of additional pro- [54] . In women in whom an acute proximal DVT or PE occurs after the 37 th week of gestation, the risk of symptomatic PE during labour is substantially increased. In these cases, a planned delivery may be benefi cial, either through the induction of labour or by elective caesarean section, because this allows events to be timed and minimises the duration of time spent without adequate anticoagulation and the risks of unscheduled delivery on full anticoagulation [8, 11, 13] . Women treated with LMWH may be switched to a continuous infusion of UFH at least 36 h before the induction of labour or caesarean section [11] . UFH has a shorter halflife and should be discontinued 4 -6 hours before planned delivery. Alternatively, if the risk of PE is estimated to be markedly increased, the infusion rate may be down-regulated (e.g., 400 -600 IE/h) [31] to maintain anticoagulation as long as possible, and the infusion may be discontinued for only the ejection phase of delivery. Infusion may then be restarted 4 -6 h after delivery if there are no bleeding complications. A retrievable inferior vena cava fi lter may also be inserted and then removed postpartum to prevent PE during delivery. However, experience with these devices is very limited, and in consideration of the potential complications, it may be best to restrict IVC fi lter insertion to women in whom anticoagulation is contraindicated or in women with proven DVT who have recurrent PE despite adequate anticoagulation [8, 9, 55, 56] . Outside pregnancy, the use of IVC fi lters has failed to provide any protection against PE, and they have been associated with serious complications [57] .
Neuraxial anaesthesia is contraindicated in pregnant women who receive anticoagulation once or twice daily at therapeutic doses. According to the current version of the European Society of Anaesthesiology (ESA) on neuraxial anaesthesia in patients receiving antithrombotic agents, the use of LMWH must be discontinued for at least 24 hours before puncture, and treatment can be resumed a minimum of 4 hours after catheter removal (Tab. IV) [58] . Spontaneous labour does not usually meet these time intervals, and the majority of anticoagulated women can therefore be expected to deliver without neuraxial anaesthesia. In women receiving UFH, heparin must be discontinued for at least 4 -6 hours if it is administered intravenously and for at least 8 -12 hours if it is administered subcutaneously before regional anaesthesia can be performed. UFH therapy can be restarted after a minimum of one hour after catheter removal or 4 -6 hours after delivery if there are no bleeding complications. If the level of anticoagulation is uncertain, aPTT testing or, in cases of LMWH, assessment of aXa levels can be helpful. In cases where an emergency caesarean section is required, it will have to be performed under general anaesthesia.
Recommendation 5 -Upon the onset of labour or at least 24 hours before the induction of labour or a caesarean section, the administration of LMWHs should be discontinued. Neuraxial anaesthesia can be performed only after a minimum of 24 hours after a therapeutic dose of LMWH or at least 4-6 hours after an intravenous infusion of UFH has been administered, when the aPTT is normal. Women on therapeutic anticoagulation who have received neuraxial anaesthesia should be monitored closely for the development of a spinal haematoma.
Postpartum anticoagulation
Despite the inconvenience of subcutaneous injections, many women prefer to stay on LMWH therapy postpartum Table IV . Neuraxial anaesthesia in patients treated with therapeutic doses of anticoagulants [58] . Minimum time intervals without anticoagulation before and after catheter placement and removal according to the recommendations of the European Society of Anaesthesiology: after 2 half-lives there will be 25 % residual anticoagulant activity, which provides attenuated protection against thrombosis and a reduced bleeding risk, which generally allows the use of neuraxial anaesthesia. After 4 -5 half-lives, anticoagulant rest-activities are expected to be as low as 3. [59] .
Warfarin is an alternative to ongoing LMWH treatment, and patients can be switched to warfarin after postpartum vaginal bleeding has subsided [8, 11, 13] . The switch to warfarin requires an overlapping period with LMWH of approximately 5 days, with frequent INR monitoring. LMWH therapy can be terminated when the INR target range -generally 2.0-3.0 -has been achieved. A case-control study revealed that larger doses of warfarin and a longer time to reach the INR target range were required in postpartum women compared to non-pregnant women [60] . When switching to warfarin, dosing should commence using the anticipated maintenance dose or a dose based on nomograms [61, 62] (Fig. 1) .
Both heparin and warfarin can be administered to breastfeeding women. In a case series of 15 women receiving LMWHs, small amounts of heparin were detected in the breast milk of 11 patients, but because neither UFH nor LMWH is orally active, no clinical eff ect would be anticipated in the infant [63] . Warfarin does not enter the breast milk in active forms and is considered safe for breastfeeding mothers. In contrast, phenprocoumon, which is more lipophilic than warfarin, is expected to be excreted into breast milk and is therefore not recommended [8, 64] .
Recommendation 6 -Anticoagulant therapy in the postpartum period can be continued using LWMH or switched to warfarin with an overlapping phase and frequent INR monitoring.
Duration of VTE secondary prevention
No studies have addressed the issue of the optimal duration in anticoagulant therapies for pregnancy-associated VTE. Based on the evidence in non-pregnant patients and considering the high proportion of pregnant patients with proximal DVT and PE and the ongoing risk of VTE during the later stages of pregnancy and the postpartum period, the current guidelines recommend that anticoagulant therapy should be continued throughout pregnancy and for at least 6 weeks postpartum; they advocate a minimum total duration of therapy of 3 months [8, 13] . Patients should be monitored using regular ultrasound examinations of the venous system. In cases of delayed or absent recanalisation of the iliac or femoral veins, the patient should be considered to be at high risk for the development of a symptomatic postthrombotic syndrome (PTS). These patients may benefi t from prolongation of anticoagulant therapy.
Recommendation 7 -By extrapolating the recommendations of current guidelines for risk-associated VTE, we found that pregnant women with acute VTE should be anticoagulated for a minimum of 3 months, at least throughout pregnancy, and for 6 weeks postpartum.
Maternal risks of anticoagulation
Most Summaries of Product Characteristics (SmPC) for antithrombotic drugs are mainly based on the fact that these drugs have not been suffi ciently tested during pregnancy and breastfeeding. For this and legal reasons, drugs are frequently considered to be contraindicated during [5] . There were no cases of fatal bleeding, but medical intervention due to severe bleeding was required in 3.4 % of the cases. The safety and effi cacy of LMWH for the treatment of VTE in pregnant patients has also been confi rmed in other observational studies [26, 27, 65 -68] . However, the number of women receiving therapeutic-dose LMWH in these studies was small; as a result of the retrospective study design, bleeding rates were potentially underestimated. This risk of postpartum haemorrhage (PPH; i.e., blood loss > 500 mL) has been observed to be approximately 5 % within the fi rst 24 hours after delivery, and occurred in 2 % of women in the days following delivery [27] . Knol et al. assessed the risk of PPH in 88 patients who were treated with therapeutic doses of nadroparine and reported a 1.9- [69] . The risk of PPH after caesarean section was 12 % (2/17) and 4 % (3/67), respectively, in women with and without anticoagulants. The risk of PPH was not substantially increased when women delivered within 12 to 24 hours after the last injection of LWMH [69, 70] . In comparison, the overall prevalence of PPH in European countries has been estimated to be approximately 6.4 %, and severe PPH is reported to occur in 1.8 % of all deliveries [71] . In a retrospective cohort study of 100 pregnancies in 77 UFH-treated women, the rate of major antepartum bleeding was 1 %, which was consistent with the bleeding rates reported to be associated with UFH and VKA therapy in non-pregnant patients [8, 72] .
Heparin-induced thrombocytopenia
A serious adverse eff ect that has been attributed to the use of LMWH and UFH is HIT. Exposure to any kind of heparin may result in an autoimmune response that is characterised by the development of IgG antibodies directed against complexes containing heparin and platelet factor 4. The subsequent immune reaction results in thrombocytopenia and endothelial damage [73, 74] . HIT is characterised by a decrease in the platelet count of at least 50 %, an onset at 5 -15 days after the initiation of heparin therapy and a prothrombotic state that places the patient at high risk for arterial and venous thrombotic complications [75] . It must be emphasised that thrombocytopenia resulting from other causes is not uncommon during pregnancy [76, 77] , and pregnancy is generally classifi ed as a low-risk condition for HIT. However, because HIT is a life-threatening complication that has been attributed to the use of heparins, the clinical suspicion of HIT requires the immediate discontinuation of therapy and a switch to a full-dose nonheparin anticoagulant treatment [48, 75] .
The quality of evidence regarding the effi cacy and safety of alternative anticoagulants during pregnancy is low. Lindhoff -Last et al. reviewed the use of danaparoid in 51 pregnancies in 49 patients identifi ed in the literature between 1981 and 2004 [16] . Women were treated for a median duration of 10 weeks with danaparoid, either because of HIT (n = 32) or due to allergic skin reactions (n = 19). Danaparoid was administered until the delivery of a healthy child in 72 % of cases. In 21.6 % of cases, treatment had to be stopped earlier as a result of adverse events, and in 5.6 % of the cases, anticoagulant therapy was terminated because it was no longer required. Four cases of maternal bleeding complications were observed during the pregnancy or postpartum periods, two of which were fatal. No aXa activity was detected in 5 samples of foetal cord blood and 3 samples of maternal breast milk. Danaparoid can be considered as an alternative anticoagulant because it has been shown to be effi cacious in cases of HIT and because it does not cross the placenta [78 -81] .
Elsaigh et al. reported on the use of fondaparinux in 13 women and 15 pregnancies [82] . Nine patients received treatment at therapeutic doses (7.5 or 10 mg/d), and six patients were treated with a lower prophylactic dose (2.5 or 5 mg/d). Only one woman experienced a recurrent VTE while on a full treatment dose. No major bleeding occurred during treatment with fondaparinux. The authors reported two cases of spontaneous pregnancy loss and one elective termination of pregnancy due to foetal anomalies (Fallot's tetralogy and Dandy-Walker syndrome). Case reports and small cohort studies reported no adverse outcomes when anticoagulant therapy was switched from heparin to fondaparinux, which occurred because of allergic skin reactions [15, 83 -85] . On the basis of current evidence, the use of fondaparinux in cases of heparin intolerance seems to be welltolerated and effi cacious during pregnancy. However, there were no cases in which fondaparinux was used to treat HIT during pregnancy. At the present time, experience with fondaparinux during pregnancy is too limited to recommend fondaparinux over danaparoid in cases of suspected HIT.
Recommendation 8 -Heparin-induced thrombocytopenia in pregnant women is extremely rare. In pregnant women suspected of having HIT, consultation with a haemostaseologist or experienced thrombosis specialist is recommended to determine whether alternative anticoagulants, such as danaparoid or fondaparinux, are needed.
Heparin-induced allergic skin reactions
Heparin-induced skin reactions are primarily caused by delayed-type hypersensitivity (DTH; so-called type IV allergic reactions) [86] . DTH reactions to heparin are clearly more common than previously believed, and have been observed in up to 20 % of women who were treated with heparins throughout pregnancy [87] . Patients usually present with an itching erythema or red plaques at the sites of heparin injections. If an allergic skin reaction occurs during pregnancy, the most pragmatic option seems to be to switch to another heparin. However, the rate of cross-reactivity between heparins is high (33 -73 %), and it has been shown that heparins with high molecular weight are more likely to induce allergic skin reactions [88] . In cases of several cross-reactions, treatment with an alternative anticoagulant, such as danaparoid or fondaparinux, may be considered.
Heparin-induced osteoporosis
Osteoporosis is a systemic skeletal disease that is characterised by a loss of mineral bone mass, alterations in bone microarchitecture and subsequent bone fragility that results in an increased risk of fractures. In particular, preg-
© 2016 Hogrefe nant women are susceptible to osteoporosis when they are being treated with heparins for long periods of time (i.e., over several weeks or months) [8] . During pregnancy, the demand for calcium is increased, leading to the mobilisation of calcium and bone resorption. In some women, excessive resorption of mineral bone mass may occur. However, so-called pregnancy-associated osteoporosis is rare and thought to be multifactorial, and has been related to dietary factors (e.g., low calcium intake and vitamin D insuffi ciency) and to genetic factors (e.g., polymorphisms in the vitamin D or oestrogen receptor) [89] . The use of heparins may also increase the rate of bone resorption [90 -93] . Osteopenia is caused by the binding of heparin to osteoclasts, which then release factors that activate osteoclasts in an interleukin 11-dependent fashion [94] . Heparin-associated osteoporotic fractures have been observed in 2-5 % of patients treated with heparin for long periods of time. Both UFH and LMWH have the potential to produce osteopenia and increase the risk of bone fractures [95, 96] . However, the fracture risk is assumed to be substantially lower for LMWH, and this has been attributed to the lower affi nity of LMWH to osteoblasts and osteoclasts [89, 97, 98] . Despite the existence of sporadic reports of symptomatic osteoporosis that occurs with the use of LMWH during pregnancy and postpartum [31, 99, 100] , LWMH are considered at least as safe and eff ective as UFH, and have replaced UFH in most situations in which long-term treatment with heparin is indicated [3, 90] . Whether the use of prophylactic calcium supplementation in expecting mothers avoids heparin-induced osteopenia and lowers the risk of bone fractures has not yet been investigated.
Foetal risks of anticoagulation
Foetal safety is an important issue when considering the use of an anticoagulant therapy during pregnancy. Heparins do not cross the placenta and therefore have no impact on the risk of foetal bleeding [8, 101, 102] . There is also no evidence indicating that teratogenicity results from the use of LMWH or UFH during pregnancy [5, 65, 103] . Because it has a high molecular weight and a negative charge, UFH also does not appear in breast milk. However, small amounts of LMWH have been detected in the breast milk of women treated with prophylactic LMWH doses after caesarean section [63] . Because the bioavailability of orally administered heparins is negligible, traces of LMWH in the breast milk are considered harmless to the child [8, 104] . Fondaparinux is a synthetic pentasaccharide factor Xa inhibitor that, like LMWH, exerts its actions via high-affi nity reversible binding to antithrombin. Knol et al. observed no foetal haemorrhages or malformations in 12 pregnant women treated with 7.5 mg fondaparinux daily during pregnancy. However, in three of these women, severe PPH occurred, and in 2 of these cases, it occurred within 12 hours after the last injection [15] . In this context, the longer half-life of fondaparinux (i.e., 15 -20 hours) compared to the half-life of LMWH (i.e., 3 -6 hours) is a disadvantage, especially during the peripartum period [45] . Moreover, Dempfl e reported that drug levels were one tenth of maternal levels in umbilical cord blood in aXa and aPTT assays [105] . Because there is a lack of appropriate data and because there is evidence for minor transplacental passage of fondaparinux, this substance is not recommended in pregnancy, and its use should be limited to patients with contraindications to heparins, such as heparininduced skin reactions or thrombocytopenia [8, 14, 15] . In addition, it is unknown whether fondaparinux is secreted into human breast milk. However, fondaparinux has been found in the milk of lactating rats, and although it is unlikely that a negatively charged oligosaccharide will pass the intestinal barrier or appear in signifi cant amounts in the neonatal blood, its use is not advocated in breast-feeding women [8] .
VKAs cross the placenta, and coumarin exposure during the fi rst trimester of pregnancy can result in severe foetal malformations [8] . Coumarin embryopathy is characteriSed by skeletal abnormalities, which include nasal hypoplasia, a depressed or narrowed nasal bridge, scoliosis, and calcifi cations in the vertebral column, femur, and heel bone that have a peculiar stippled appearance on X-rays. Limb abnormalities, such as brachydactyly or underdeveloped extremities, can also occur. In later pregnancy, coumarins increase the risk of pregnancy loss and foetal bleeding complications. Common non-skeletal features include low birth weight and developmental disabilities. The use of warfarin throughout pregnancy is associated with a congenital anomaly rate of 3.7 -6.4 % [106, 107] . In a European prospective multicentre study that included 666 pregnant women exposed to VKA, only two coumarin embryopathies were observed in the women exposed to phenprocoumon during the fi rst trimester, resulting in an incidence rate of 0.6 % [108] . Because they have the potential to harm the foetus, the use of VKA to treat uncomplicated pregnancyassociated VTE cannot be recommended.
Warfarin and acenocoumraol can be prescribed to lactating women. Because both molecules are polar, non-lipophilic and highly protein-bound, they are not expected to appear in signifi cant amounts in breast milk [8, 64] . In contrast, concerns have been raised regarding the use of the less polar, more lipophilic VKA, such as phenprocoumon, which might be excreted into breast milk and should therefore be avoided in breast-feeding women.
Pregnant and breast-feeding women were excluded from trials evaluating new oral direct thrombin and factor Xa inhibitors. Because these drugs are relatively small molecules, they are thought to cross the placental barrier, and should therefore be avoided during pregnancy [17, 109] . The teratogenicity of dabigatran and rivaroxaban has been described in animal studies [8, 17, 20] . Rivaroxaban has also been reported to be secreted into breast milk. Therefore, the manufacturers of dabigatran and rivaroxaban both recommend against using these medications in breast-feeding women. Therapeutic options in life-threatening PE
Thrombolytic therapy
The maternal and foetal risks of thrombolytic therapy have not been adequately studied. Although recombinant tissue plasminogen activator (rt-PA) and streptokinase are large molecules, minimal transplacental passage has been demonstrated for these drugs, and there are therefore concerns about severe adverse eff ects, such as bleeding complications, pregnancy loss, premature labour and placental abruption [110 -112] . The maternal risk of bleeding, mostly from the genital tract, has been described to be approximately 6 -8 %, which is consistent with the risk in non-pregnant patients receiving thrombolytic therapy [11] . A 6 % rate of foetal loss and a 6 % rate of pre-term delivery have been reported [110] . However, the overall number of cases with successful systemic thrombolysis in pregnancy is small, and a publication bias resulting from a predominance of cases with a favourable outcome must be taken into account. The treatment of VTE using systemic thrombolysis must therefore be regarded as relatively contraindicated during pregnancy and in the peripartum period, and should be reserved for life-threatening cases of PE [1, 8, 9, 11] .
UFH is recommended as the initial anticoagulant in patients with suspected PE and haemodynamic compromise (e.g., hypotension, tachycardia, refractory hypoxaemia, collapse or shock) because of its rapid eff ect and short half-life, which allow for dose-adjustment, especially if thrombolysis is considered [1, 9, 13] . After haemodynamic stabilisation, therapy can be switched to LMWH. In the case of systemic thrombolysis, it has been recommended to omit the UFH loading dose and start infusion at a rate of 18 U/kg/h in parallel with or after the administration of the thrombolytic agent [9] . If the patient is not suitable for thrombolysis or if thrombolysis has failed, catheter-assisted endovascular or surgical embolectomy must be considered. The decision regarding which method should be applied depends on the local expertise and available resources.
Recommendation 9 -Systemic thrombolysis in pregnancy should only be considered in life-threatening PE because of possible maternal and foetal risks.
Inferior vena cava fi lters
In the recently published PREPIC-2 trial, the addition of the insertion of a retrievable IVC fi lter for 3 months to anticoagulant therapy provided no benefi t in terms of PE recurrence or mortality in non-pregnant patients presenting with acute symptomatic PE [57] . Therefore, fi lter insertion into the IVC in pregnant women treated with anticoagulants cannot be recommended and should be restricted to women with severe contraindications against anticoagulant therapy or in those with recurrent PE despite adequate anticoagulation. Temporary fi lter placement may also be considered in the peripartum period if acute iliofemoral DVT occurs after the 36 th week of gestation. Because their use in pregnant women is limited to case reports or small case series, it remains uncertain whether they are beneficial in this setting [113 -116] . Each case requires individual assessment, and the risks of fi lter placement and complications, such as fi lter migration (20 % of cases), fi lter fracture (5 % of cases) and fi lter perforation (up to 5 % of cases), has to be considered. In addition, the radiation time required for fi lter placement must be considered. According to the literature, a radiation time < 2 minutes is estimated, which will yield a radiation dose < 5 mSv with abdominal shielding [117] .
Recommendation 10 -The use of IVC fi lters is not recommen-ded in pregnancy-associated VTE unless recurrent PE occurs despite adequate anticoagulation or when severe contrain-dications to anticoagulant therapy exist.
Therapeutic options in limb-threatening DVT
A delay or failure of venous recanalisation, in particular if the iliac or femoral veins remain occluded, has been identifi ed as a substantial risk factor for the development of drome (PTS). In non-pregnant patients, strategies involving early thrombus removal using either endovascular or surgical techniques must be considered [118] . It remains unclear whether these treatment options are also a safe and eff ective alternative in pregnant women. In a case series, Herrera et al. presented outcome data for 13 pregnant women with extensive DVT involving the iliofemoral veins who were treated with catheter-directed or pharmacomechanical thrombolysis (n = 11) or surgical (n = 2) venous thrombectomy [119] . After a mean follow-up of 1.3 years (range 1 -74 months), venous duplex ultrasound revealed patent veins in 12/13 patients (92 %) and normal valve functions in 10/13 patients (77 %). In 11/13 patients (85 %), Villalta scores were < 5, indicating no relevant post-thrombotic sequelae. Concerns have been raised regarding radiation doses ranging between 55 and 450 mGy and the risk of complications, such as major bleeding with the need for transfusion (n = 2), puncture site haematoma (n = 3) and popliteal artery pseudoaneurysm (n = 1). The risks and benefi ts of these invasive techniques should be assessed in further prospective studies. Long-term outcomes after pregnancy-associated VTE
Post-thrombotic syndrome
Because pregnancy-associated DVT often involves the iliac and femoral veins, a substantial number of women are thought to develop long-term sequelae following extensive DVT. In a sub-analysis from the Home-LITE study, Hull et al. compared the long-term use of tinzaparin (i.e., for more than 12 weeks) versus the administration of tinzaparin for 5 days followed by warfarin for 12 weeks in patients with proximal DVT, and reported a lower frequency of PTS in patients who received prolonged treatment with LMWH [120] . The benefi ts of a prolonged LMWH therapy were even greater for iliac vein thrombosis than for DVT not involving the iliac veins. Although this study was conducted in non-pregnant patients, the results may be relevant to pregnancy-associated DVT because iliac vein thrombosis is more common during pregnancy, and favourable eff ects from long-term LMWH treatment during pregnancy can therefore be expected. Clinical data related to long-term outcomes after pregnancy-associated VTE are scarce. The typical symptoms of PTS are persistent leg swelling, pain, cramps, heaviness, paraesthesia, hyperpigmentation, venous ectasia, and sometimes overt ulcers that can develop months or years after the acute thrombotic event. In nonpregnant patients, PTS is associated with a substantially increased risk for VTE recurrence. Outside pregnancy, the clinical symptoms of PTS persist in 25 -50 % of cases after DVT, and severe PTS has been reported to occur in approximately 5 -10 % of cases [121] . Comparable outcomes have been observed for pregnancy-associated DVT. In a long-term follow-up over 3 -16 years, women with pregnancy-associated DVT developed any degree of PTS in 42 % of cases and severe PTS in 7 % of cases, with postnatal proximal DVT being the strongest risk factor for PTS (OR 6.3; 95 % CI 2.0 -19.8) [122] .
Compression therapy
In the case of DVT and pronounced swelling in a lower limb, leg elevation and compression bandages should be used during the acute phase to reduce pain and oedema. Whenever possible, the woman should be kept mobilised along with compression therapy, which is recommended to be continued with fi tted graduated elastic compression stockings (GCS; class 2, corresponding to a pressure of 23-32 mmHg) as soon as the leg swelling declines. Data from trials performed in non-pregnant patients suggest that the incidence of PTS can be reduced by 50 % if compression therapy is continued for two years [9] . In contrast, the recently published placebo-controlled SOX study was unable to confi rm benefi cial eff ects of compression therapy on the incidence of PTS, but this may be the result of a low compliance rate (i.e., 55.6 %) [123] . Because of weaknesses in the design of this study, current German guidelines continue to recommend compression treatment [21] . There is no doubt that GCS improves symptoms in patients by reducing pain and leg swelling [124] . Furthermore, GCS were shown to reduce venous vessel diameters and increase blood fl ow velocity in the common femoral vein in postpartal DVT, which can reduce venous stasis and may improve venous function in the long-term [125] .
Recommendation 12 -Compression therapy involving the use of compression bandages or graduated compression stockings is recommended, at least throughout pregnancy and the postpartum period because this relieves symptoms during the early phase and prevents later sequelae such as PTS. Based on data from nonpregnant populations, compression therapy after proximal DVT should be continued for at least 2 years and longer if symptoms of PTS persist.
Conclusions
Because there is a lack of adequate study data, management strategies for pregnancy-associated VTE must be deduced from small observational studies and extrapolated from recommendations for non-pregnant patients. On the basis of current evidence, weight-adjusted, full-dose LMWH is the anticoagulant treatment of choice during pregnancy. A once or twice daily LMWH dosing regimen is possible, but a twice daily dosing regimen seems to be advisable, at least perinatally. It remains unclear whether adjusting doses according to factor Xa activity provides any benefi t. The management of delivery deserves special care and attention and depends on the time interval between the diagnosis of VTE and the expected delivery date. In particular, if VTE manifests at term, delivery should be attended by an experienced multidisciplinary team. The different anticoagulant management strategies currently in use are summarised in Figure 2 . We conclude that there is an urgent need for well-designed prospective studies to compare diff erent management strategies in women with pregnancy-associated VTE. 
